Nanexa: Moments of truth closing in - Redeye

Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nordisk. We believe upcoming events regarding the clinical development of NEX-20 and NEX-22 bode well for the share price development, and that Nanexa’s investment agreement with Novo Nordisk could also generate shareholder value.

Länk till analysen i sin helhet: https://www.redeye.se/research/910417/nanexa-moments-of-truth-closing-in?utm_source=finwire&utm_medium=RSS